These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 37541769)

  • 1. Talazoparib (Talzenna) for prostate cancer.
    Med Lett Drugs Ther; 2023 Aug; 65(1682):e134-e135. PubMed ID: 37541769
    [No Abstract]   [Full Text] [Related]  

  • 2. In brief: A new prostate cancer indication for olaparib (Lynparza).
    Med Lett Drugs Ther; 2023 Jun; 65(1679):e106-e107. PubMed ID: 37339094
    [No Abstract]   [Full Text] [Related]  

  • 3. Talazoparib: a new biomarker-directed therapy in advanced prostate cancer.
    Conteduca V; De Giorgi U
    Lancet Oncol; 2021 Sep; 22(9):1203-1204. PubMed ID: 34388387
    [No Abstract]   [Full Text] [Related]  

  • 4. Apalutamide (Erleada) for prostate cancer.
    Med Lett Drugs Ther; 2018 Jul; 60(1551):e124-e125. PubMed ID: 30036351
    [No Abstract]   [Full Text] [Related]  

  • 5. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
    de Bono JS; Mehra N; Scagliotti GV; Castro E; Dorff T; Stirling A; Stenzl A; Fleming MT; Higano CS; Saad F; Buttigliero C; van Oort IM; Laird AD; Mata M; Chen HC; Healy CG; Czibere A; Fizazi K
    Lancet Oncol; 2021 Sep; 22(9):1250-1264. PubMed ID: 34388386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Talazoparib to treat BRCA-positive breast cancer.
    Guney Eskiler G
    Drugs Today (Barc); 2019 Jul; 55(7):459-467. PubMed ID: 31347614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Talazoparib for newly diagnosed prostate cancer associated with significant risk reduction of disease progression.
    Nierengarten MB
    Cancer; 2023 Aug; 129(15):2277. PubMed ID: 37401897
    [No Abstract]   [Full Text] [Related]  

  • 8. Phototoxic eruption caused by enzalutamide (Xtandi).
    Navarro-Triviño FJ; Ruiz-Villaverde R
    Contact Dermatitis; 2021 Jan; 84(1):64-65. PubMed ID: 32865823
    [No Abstract]   [Full Text] [Related]  

  • 9. Enzalutamide (Xtandi) for prostate cancer.
    Med Lett Drugs Ther; 2013 Mar; 55(1411):e20. PubMed ID: 23467121
    [No Abstract]   [Full Text] [Related]  

  • 10. A drug safety evaluation of enzalutamide to treat advanced prostate cancer.
    Saad F; Hamilou Z; Lattouf JB
    Expert Opin Drug Saf; 2021 Jul; 20(7):741-749. PubMed ID: 34114527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses.
    Mehra N; Fizazi K; de Bono JS; Barthélémy P; Dorff T; Stirling A; Machiels JP; Bimbatti D; Kilari D; Dumez H; Buttigliero C; van Oort IM; Castro E; Chen HC; Di Santo N; DeAnnuntis L; Healy CG; Scagliotti GV
    Oncologist; 2022 Oct; 27(10):e783-e795. PubMed ID: 36124924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PMDA regulatory update on approval of new drugs and revisions of precautions; approval of talazoparib tosilate for prostate and breast cancer, and luspatercept for myelodysplastic syndrome in Japan.
    Matsumura N; Mandai M
    Int J Clin Oncol; 2024 May; 29(5):493-494. PubMed ID: 38551728
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Clinical Trial.
    Vaishampayan UN; Heilbrun LK; Monk P; Tejwani S; Sonpavde G; Hwang C; Smith D; Jasti P; Dobson K; Dickow B; Heath EI; Semaan L; Cher ML; Fontana JA; Chinni S
    JAMA Netw Open; 2021 Jan; 4(1):e2034633. PubMed ID: 33496795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-PD-L1 plus enzalutamide does not improve overall survival in prostate cancer.
    Siddiqui BA; Subudhi SK; Sharma P
    Cell Rep Med; 2022 Apr; 3(4):100613. PubMed ID: 35492243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enzalutamide With Radiation Therapy for Intermediate-Risk Prostate Cancer: A Phase 2 Study.
    Kaplan I; Bubley GJ; Bhatt RS; Taplin ME; Dowling S; Mahoney K; Werner E; Nguyen P
    Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1416-1422. PubMed ID: 33636278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. YAP1 overexpression contributes to the development of enzalutamide resistance by induction of cancer stemness and lipid metabolism in prostate cancer.
    Lee HC; Ou CH; Huang YC; Hou PC; Creighton CJ; Lin YS; Hu CY; Lin SC
    Oncogene; 2021 Apr; 40(13):2407-2421. PubMed ID: 33664454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KIF15-Mediated Stabilization of AR and AR-V7 Contributes to Enzalutamide Resistance in Prostate Cancer.
    Gao L; Zhang W; Zhang J; Liu J; Sun F; Liu H; Hu J; Wang X; Wang X; Su P; Chen S; Qu S; Shi B; Xiong X; Chen W; Dong X; Han B
    Cancer Res; 2021 Feb; 81(4):1026-1039. PubMed ID: 33277366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Establishment of enzalutamide-resistant human prostate cancer cell lines and screening of lncRNA and mRNA expression profiles].
    Guan H; Ling ZX; Fang F; Mao LK; You ZH; Wang C; Chen SQ; Xu B; Chen M
    Zhonghua Nan Ke Xue; 2018 Feb; 24(2):116-121. PubMed ID: 30156069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Darolutamide (Nubeqa) for prostate cancer.
    Med Lett Drugs Ther; 2019 Dec; 61(1587):201-202. PubMed ID: 31999669
    [No Abstract]   [Full Text] [Related]  

  • 20. Enzalutamide shows sustained overall survival improvement in patients with metastatic hormone-sensitive prostate cancer.
    Nierengarten MB
    Cancer; 2023 Aug; 129(15):2278. PubMed ID: 37401895
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.